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Testicular germ cell tumours of adults and adolescents (TGCT) include seminomas (SE) and nonseminomas (NS), with spermatocytic
seminomas (SSE) representing a distinct entity in older men. SE and NS have gain of 12p material in all cases, whereas SSE are
associated with overrepresentation of chromosome 9. Here, we compare at the chromosomal level, copy number imbalances with
global expression changes, identified by comparative expressed sequence hybridisation analyses, in seven SE, one combined tumour,
seven NS and seven cell lines. Positive correlations were found consistent with copy number as a main driver of expression change,
despite reported differences in methylation status in SE and NS. Analysis of chromosomal copy number and expression data could
not distinguish between SE and NS, in-keeping with a similar genetic pathogenesis. However, increased expression from 4q22, 5q23.2
and 9p21 distinguished SSE from SE and NS and decreased copy number and expression from 2q36–q37 and 6q24 was a specific
feature of NS-derived cell lines. Our analysis also highlights 19 regions with both copy number and expression imbalances in greater
than 40% of cases. Mining available expression array data identified genes from these regions as candidates for involvement in TGCT
development. Supplementary data is available at http://www.crukdmf.icr.ac.uk/array/array.html.
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Adult germ cell tumours of the testis can be grouped by age of
incidence and differentiation status into two main entities
(Oosterhuis and Looijenga, 2005). Firstly, testicular germ cell
tumours (TGCT) of adults and adolescents. These are the most
common malignancy in males aged 20–40 years (Horwich et al,
1991) accounting for 60% of all male malignancies in this age
group (Ulbright, 1993). TGCT can be classified into two main
subtypes, seminoma (SE) and nonseminoma (NS). SE have a
median age at diagnosis of 35 and resemble primordial germ cells
(PGC)/gonocytes, the cells from which both these subtypes are
generally thought to be derived. NS, which have a median age at
diagnosis of 25, exhibit various stages of differentiation with cells
from embryonic, extra-embryonic and somatic tissue types
(Mostofi, 1973). Material from the short arm of chromosome 12
is invariably gained in these tumours and in roughly 10% of cases a
smaller region of gain at 12p11.2–p12.1 has been defined
(Rodriguez et al, 2003; Zafarana et al, 2003).
Secondly, spermatocytic seminomas (SSE) are also testicular
tumours of germ cell origin, however, they are generally restricted
to men aged over 50 years (Oosterhuis and Looijenga, 2005). The
genomic imprinting in SSE has a paternal pattern that is different
to that of SE and NS, which generally show an erased pattern of
imprinting. This is consistent with SSE being derived from a more
differentiated germ cell in the spermatogenic lineage than SE or NS
(Verkerk et al, 1997). Unlike the TGCT of adults and adolescents,
gain of 12p material is not a feature of these tumours. However,
gain of chromosome 9 is associated with SSE and array
comparative genomic hybridisation analysis identified amplifica-
tion of 9p21.3-ter and the likely involvement of the DMRT1 gene
(Looijenga et al, 2006).
Cytogenetic, comparative genomic hybridisation (CGH) and
allelic imbalance studies of SE and NS have shown that a number
of regions in addition to 12p are imbalanced. Reported frequent
aberrations common to both SE and NS include gain of material
from chromosomes 1, 7, 8, 17, 21 and X and loss of material from
chromosomes 4, 5, 11, 13, 18 and Y (van Echten et al, 1995; Korn
et al, 1996; Mostert et al, 1996; Sandberg et al, 1996; Summersgill
et al, 1998a,b; Kraggerud et al, 2002; von Eyben et al, 2004). In
recent years, a number of expression profiling studies have been
reported and these have identified overexpressed genes and
expression signatures, which distinguish different subtypes of NS
(Skotheim et al, 2005). Although we have previously examined
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(Rodriguez et al, 2003), few studies have integrated genomic and
expression array data for the entire genome of TGCT (Skotheim
et al, 2006). Factors predicted to influence gene expression include
genomic copy number and epigenetic factors such as methylation.
The level of methylation in TGCT varies between the subtypes and
previous studies have found that SE have a lower level of CpG
island methylation than NS (Smiraglia et al, 2002; Zhang et al,
2005).
Here, we investigate a series of SSE, SE, NS and cell lines using
the approach of comparative expressed sequence hybridisation
(CESH) (Lu et al, 2001) to determine a global chromosomal level
view of the expression patterns in these tumours. This and CGH
data are analysed to determine the relationship between expression
patterns and copy number imbalances. In conjunction with
published data for SE and NS, regions of imbalance associated
with differentially expressed genes in greater than 40% of cases
were identified. In addition, changes in expression are identified
which differentiate between TGCT, NS-derived cell lines and SSE.
MATERIALS AND METHODS
Snap-frozen primary tumour samples were collected from
histologically verified SE (26), NS (24), combined tumours (CT)
(6) and SSE (5) obtained from patients attending the Royal
Marsden Hospital NHS Trust and Erasmus MC University Medical
Center, Rotterdam (Supplementary Table 1). Informed patient
consent and ethical approval were obtained for the use of the
material in this study in accordance with the Helsinki Declaration.
In addition, nine cell lines derived from NS tumours and one
derived from a SE were also included in the study. These were
GCT27, GCT44, Tera1, Tera2, H12.2, 2102Ep, 577MF, NTERA2,
SUSA and TCam-2. The cell lines were cultured as described
previously (Pera et al, 1987; Kelland et al, 1992; Mizuno et al, 1993;
Summersgill et al, 2001; Goddard et al, 2007). A pool of 45
individual samples of normal testis RNA was available from
Clontech (Mountain View, CA, USA) and normal DNA from Sigma
(St Louis, MO, USA). Information as to which samples were
studied by CGH and CESH can be found in Supplementary Table 1
at http://www.crukdmf.icr.ac.uk/array/array.html.
Comparative genomic hybridisation
CGH was performed as described previously (Summersgill et al,
1998b) using genomic DNA prepared by standard procedures from
patient tissue, cell lines, together with normal reference DNA.
Images were captured using a cooled CCD Photometrics camera
with SmartCapture software (Digital Scientific, Cambridge, UK).
Image analysis was carried out using Quips-XL software (Vysis
Inc., Des Plaines, IL, USA). At least five representative images were
fully analysed and the results from these were studied separately
and also combined to produce an average fluorescence ratio for
each chromosome. A copy number change was indicated when the
average fluorescence ratio lay outside the normal range which was
determined in control experiments using differentially labelled
normal DNA.
Comparative expressed sequence hybridisation
CESH analysis was carried out as described previously (Lu et al,
2001) using the same capture system and software as for CGH
analysis. Five good quality metaphases with 320–450 band
resolution were analysed for each case using the Quips CGH
analysis software (Vysis) to produce an average profile of the
fluorescence intensity ratios. Unlike CGH, the CESH ratios of
fluorescence frequently change within a small chromosomal
region. Misalignment in averaged profiles can reduce resolution
and therefore two or three metaphases with less condensed
chromosomes (around 700 band resolution) were also examined
individually to precisely define chromosome bands containing
differentially expressing genes.
Data analysis
Gain and loss of chromosomal regions from CGH and gene over-
and underexpression from CESH analysis were recorded in Excel
spreadsheet format. For each chromosomal band, gain/over-
expression was indicated by 1, loss/underexpression by  1 and
no change by 0. From this the frequency of aberrations could be
calculated. The data, which were subject to unsupervised clustering
analysis, were collected using Clustan (http://www.clustan.com).
The data were also subject to supervised learning method PAM
(prediction analysis for microarray) (Tibshirani et al, 2002), which
was used to identify expression pattern associated with specific
histology. This is carried out by a penalised t-statistic, which ranks
the elements and a soft-thresholding to identify the set of
overexpress regions for classification. To analyse correlations
between copy number and expression data the Spearman’s rho test
was used.
RESULTS
Identification of regions of frequent copy number and
expression alteration
26 SE-, 6 CT-, 24 NS- and 7 NS-derived cell lines were investigated
by metaphase CGH. 7 SE-, 1 CT-, 7 NS- and 9 NS-derived cell lines,
1 SE-derived cell line and 5 SSE were investigated by CESH.
Metaphase CGH and CESH data were divided based on subtype
and the frequency of aberrations at each chromosomal region was
calculated. Frequency plots of imbalances can be seen in Figure 1.
Regions of copy number and expression imbalance, which had a
frequency of greater than 40% were identified. This identified 42
regions of copy number and 50 regions of expression in addition to
the 12p in SE-, NS-, NS-derived cell lines. Analysis of SSE CESH
data determined 43 regions of expression imbalance. Comparison
between the copy number and expression data highlighted the
importance of 20 regions denoted in Table 1. These regions had
overlapping copy number and expression imbalances in SE, NS or
TGCT cell lines. All identified regions of copy number and
expression imbalance can be seen in Supplementary Tables 2
(CGH data) and 3 (CESH data)(http://www.crukdmf.icr.ac.uk/
array/array.html).
Identification of regions that are significantly different
between tumour subtypes
Supervised learning of the SE, CT, NS and cell lines CGH data
found that loss of two regions at 22q11–q13.3 and 2q14.1–q31
were associated with the cell lines. No other differences were found
or could be determined with unsupervised clustering. Prediction
analysis of the CESH data could not find significant differences
between the SE and NS. However, differences in expression
patterns between the primary TGCT (SE and NS), cell lines and
SSE were found (Figure 2). These included 12p11–p13.3, which
was overexpressed in SE, NS and cell lines but not in SSE. The
chromosome bands 2q31, 2q35, 2q36 and 2q37 were associated
with overexpression in SE, NS and SSE but underexpression in cell
lines. Overexpression from 4q22 and 9p21 was associated with SSE.
Relationship between copy number and expression in SE
and NS
To determine any relationship between the copy number and
expression alterations correlations between the parallel CGH and
Copy number and expression patterns in TGCT
A McIntyre et al
1708
British Journal of Cancer (2007) 97(12), 1707–1712 & 2007 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sSE CGH
0
0.8
0.6
0.4
0.2
–0.2
–0.4
–0.6
–0.8
–1.0
1.0
NS CGH
SE CESH NS CESH
A
b
e
r
r
a
t
i
o
n
 
f
r
e
q
u
e
n
c
y
0
0.8
0.6
0.4
0.2
–0.2
–0.4
–0.6
–0.8
–1.0
1.0
A
b
e
r
r
a
t
i
o
n
 
f
r
e
q
u
e
n
c
y
0.8
0.6
0.4
0.2
0
–0.2
–0.4
–0.6
–0.8
–1.0
1.0
A
b
e
r
r
a
t
i
o
n
 
f
r
e
q
u
e
n
c
y
0.00
0.80
0.60
0.40
0.20
–0.20
–0.40
–0.60
–0.80
–1.00
1.00
A
b
e
r
r
a
t
i
o
n
 
f
r
e
q
u
e
n
c
y
0.00
0.80
0.60
0.40
0.20
–0.20
–0.40
–0.60
–0.80
–1.00
1.00
A
b
e
r
r
a
t
i
o
n
 
f
r
e
q
u
e
n
c
y
0.00
0.80
0.60
0.40
0.20
–0.20
–0.40
–0.60
–0.80
–1.00
1.00
A
b
e
r
r
a
t
i
o
n
 
f
r
e
q
u
e
n
c
y
0.00
0.80
0.60
0.40
0.20
–0.20
–0.40
–0.60
–0.80
–1.00
1.00
A
b
e
r
r
a
t
i
o
n
 
f
r
e
q
u
e
n
c
y
0.00
0.80
0.60
0.40
0.20
–0.20
–0.40
–0.60
–0.80
–1.00
1.00
A
b
e
r
r
a
t
i
o
n
 
f
r
e
q
u
e
n
c
y
Cytoband Cytoband
Cytoband
Cytoband
Cytoband Cytoband
CT CGH
SSE CESH
Cell lines CGH 
Cell lines CESH
Cytoband
Cytoband
AB
CD
EF
GH
Figure 1 Frequency plots of copy number and expression imbalances in the different subtypes. The frequency of copy number and expression
aberrations (X-axis) is plotted against the chromosomal location (Y axis) for each subtype. Graphs show the proportion of samples, which have copy number
or expression aberrations where a positive frequency is equal to proportion of samples with increased copy number or expression and negative frequency
equal to the proportion of samples with decreased copy number or expression at each chromosome cytoband. 26 SE, 24 NS, 6 CT and 7 cell lines were
analysed by CGH. 7SE, 7NS, 10 cell lines and 5 SSE were analysed by CESH. (A), (B), (E) and (F) are the frequency plots for copy number aberrations
determined by CGH for SE, NS, TGCT cell lines and combined tumours, respectively. (C), (D), (G) and (H) are the frequency plots for expression changes
determined by CESH for SE, NS, TGCT cell lines and SSE, respectively.
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tumours and cell lines except one NS primary sample showed a
significant correlation. The Spearman’s rho correlation coefficients
ranged from 0.089 to 0.719 with an average of 0.267. There was no
significant difference in the strength of the correlation between the
subtypes or their differentiation status using the student’s t-test.
Table 1 Regions of overlapping copy number and expression imbalance with a frequency of greater than 40%
CGH Frequency CESH Frequency CGH Frequency CESH Frequency
SE gain SE loss
2q31 42 2q31 43 11q12 q25 58 1q24 q25 43
7p22–q36 65 7p15.3–p13 43 18p11.32–p11.2 46 18p11.2 57
8p23.2–q24.3 65 8q21 71 18q12.3 q23 45 18q21.1 q21.3 57
12p13.3–q13.3 100 12p12.3–p11 100
21q11–q22.3 54 21q11 43
Xp22.3–p22.1 45 Xp21.3 71
Xp11.4–p11.3 42 Xp11.4–p11.3 57
Xp13.3–q28 54 Xp13.2 q21.1 57
NS gain NS loss
7p22–q36 63 7p21.1–p21.2 43 5q14 q21.1 50 5q13.1 q13.3 43
8q12–q24.3 70 8q21 57
12p13.3–p11 100 12p13.1–p11 86
Xp11.4–q28 63 Xp11.22–p11.21 43
Xp11.4–q28 54 Xq22.1 57
Cell line gain Cell line loss
1q21.3–q44 88 1q21.2 q22 44 2q14.1 q36 50 2q36 90
1q21.3–q44 88 1q32.1 q32.2 44 4q25 q35 75 4q28 44
12p13.3–q24.33 100 12p12.3–p11 100 6q25 q27 50 6q26 70
Xp21.3 75 Xp21.3 80 9q31 q33 57 9q31 70
Xp11.4–q27 63 Xp11.4 80 10q11 q22.3 50 10p12.3–p11 44
15q11 q24 63 15q21 q23 40
18q21.2 q23 50 18q21.1 q21.3 56
CESH¼comparative expressed sequence hybridisation; CGH¼comparative genomic hybridisation; SE¼seminoma; NS¼non-seminoma. 26 SE, 24 NS and 7 cell lines were
analysed by CGH. 7SE, 7NS and 10 cell lines were analysed by CESH.
Cell lines
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Figure 2 Supervised learning of CESH data. (A) Loci that are differentially expressed between TGCT and SSE. (B) Loci that are differentially expressed
between primary tumours and cell lines. Each box plot represents a chromosome locus identified as discriminatory between the groups, separated by
dashed lines. Group 1 (left): primary SE and NS samples; Group 2 (middle): NS-derived cell lines; Group 3 (right): primary SSE samples. Each circle
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number and expression changes between regions of gain or loss.
DISCUSSION
Our analysis of copy number and associated differential expression
highlights regions likely to be involved in TGCT development. It
also illustrates molecular similarities and differences between types
and subtypes of these tumours. We identified three novel regions
(2q31, 18p11.2 and 21q11) of copy number and expression change
in SE and NS. We also defined differential expression to single
cytogenetic bands within a number of regions previously
characterised with frequent copy number changes.
Three regions showed copy number and expression changes at a
high frequency that were consistent with our previous array CGH
s t u d yo fT G C T( M c I n t y r eet al, 2004). These regions are 7p22 (0.87–
2.02Mb), 8q21 (86.46–90.69Mb) and Xq22 (101.54–101.71). Over-
expression from 8q21 was found at particularly high frequency
involving 71% of SE and 57% of NS. The 8q21 region is frequently
gained and amplified in other tumour types, including breast, lung
and ovarian cancer (Balleine et al,2 0 0 0 ;B y r n eet al, 2005; Zhu et al,
2007). Tumour protein D52 isoform 2 (TPD52) encoded by a gene at
8q21.1 is described as the target for amplification of this region in
breast and ovarian cancers (Balleine et al, 2000; Byrne et al, 2005).
Mining of published expression microarray data for TGCTs (Sperger
et al, 2003) revealed increased expression of TPD52 in TGCT com-
pared to normal testis with an average fold increase of 3.2 and
represents a good candidate for involvement in TGCT. Other
differentially expressed genes in regions of imbalance were identified
including cell division cycle associated 7 (CDCA7) localised to 2q31,
which had an average 4.9-fold increase in expression compared with
normal testis. CDCA7 is a downstream target of MYC and is
frequently overexpressed in human cancers (Osthus et al, 2005).
Prediction analysis using the regions of differential expression
in TGCT subtypes identified discriminating regions in the SSE,
TGCT samples and cell lines. These regions included known
differences of 12p overexpression associated with TGCT (Rodriguez
et al, 2003) and 9p21 associated with SSE (Looijenga et al, 2006).
Novel differences included overexpression from 4q22 and 5q23.2
associated with SSE. Prediction analysis also highlighted differ-
ences between TGCT cell lines and primary tumours at both the
copy number and expression levels. These differences may reflect
their adaptive response to in vitro culturing and limit their
usefulness as models of TGCT. However, the majority of regions
found in primary tumour material were also found in the cell lines
(Table 1; Supplementary Tables 2 and 3).
Our analysis could not find any difference at the genomic or
expression level between the SE and NS studied. This provides
further evidence that the two subtypes have a similar genetic
pathogenesis. Consistent with this is the high incidence of
combined tumours (B10%), which contain elements of both
subtypes, and evidence supporting development of NS from SE
(Raja et al, 1992). Many regions of differential expression were
similar in the SSE and the TGCT of adults and adolescents. This
may reflect the male germ cell origin of these tumours, which is
proposed to differ only in differentiation status between the SSE
and TGCT (Oosterhuis and Looijenga, 2005).
Although variable correlation coefficients were found between
copy number and expression imbalances, there was a positive
correlation in nearly all cases. This indicates that copy number
imbalances have a strong effect on the expression patterns and are
a major mechanism for aberrant expression in the majority of
these tumours. No significant differences were identified in the
strength of the correlations between expression and genomic copy
number in the different subtypes and in differentiated vs non-
differentiated tumours. This may suggest that the total effect on
expression levels of mechanisms other than chromosomal
imbalances is similar in the different subtypes of TGCT. This is
despite reported differences in the frequency of CpG island
methylation of 0.08% in SE compared to 1.11% in NS (Smiraglia
et al, 2002; Zhang et al, 2005).
A number of regions of copy number change were not
associated with an expression change. Similarly, a number of
regions were found to have expression changes, but no copy
number changes. Similar patterns were found in a study of the
metaphase CGH data and expression array data for the preinvasive
stage of TGCT of adults and adolescents (Almstrup et al, 2005).
Many of the genes found overexpressed without associated
aberrant copy number are involved in maintenance of pluri-
potency (e.g. POU5F1 and NANOG) and are also highly expressed
in PGCs (Almstrup et al, 2005). This is likely to reflect the
embryonic stem cell-like nature of these tumours rather than a de
novo change associated with development of the tumour.
The results presented here highlight correlations between
genomic changes and global expression patterns, which suggests
that copy number changes play a major role in the expression
levels of genes from particular loci in TGCT. Expression patterns
showed both similarities and differences at specific regions in
TGCT, SSE and derived cell lines. This likely reflects their genetic
pathogenesis and common cellular origin. We have defined a
number of chromosome regions with a high frequency of both
copy number and expression change in TGCT. These require
further investigation to implicate oncogenes and tumour suppres-
sor genes in the development of these tumours.
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